This workshop will engage invited stakeholders and key opinion leaders with expertise in the assessment of nitrosamines (NA), including Nitrosamine Drug Substance-related Impurities (NDSRI) detection and evaluation in order to achieve the following:
FDA-HESI Research Roadmap Planning on Hazard and Risk Assessment of Nitrosamine Impurities in Drugs
May 31, 2023 – June 1, 2023
Webcast, Washington DC